The cost-effectiveness of Docetaxel and active symptom control versus active symptom control alone for refractory oesophagogastric adenocarcinoma: Economic analysis of the COUGAR-02 trial

Meads, DM, Marshall, A, Hulme, CT et al. (2 more authors) (2016) The cost-effectiveness of Docetaxel and active symptom control versus active symptom control alone for refractory oesophagogastric adenocarcinoma: Economic analysis of the COUGAR-02 trial. PharmacoEconomics, 34 (1). pp. 33-42. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
  • Meads, DM
  • Marshall, A
  • Hulme, CT
  • Dunn, JA
  • Ford, HER
Copyright, Publisher and Additional Information: © 2015, Springer. This is an author produced version of a paper published in PharmacoEconomics. Uploaded in accordance with the publisher's self-archiving policy. The final publication is available at Springer via http://dx.doi.org/10.1007/s40273-015-0324-5e
Dates:
  • Published: 1 January 2016
  • Accepted: 18 August 2015
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Health Economics (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 01 Oct 2015 08:15
Last Modified: 06 Nov 2017 10:46
Published Version: http://dx.doi.org/10.1007/s40273-015-0324-5
Status: Published
Publisher: Springer Verlag
Identification Number: https://doi.org/10.1007/s40273-015-0324-5

Share / Export

Statistics